||5R01CA218496-04 Interpret this number
||Sloan-Kettering Inst Can Research
||Assessment of Sensory Gating, Attention, and Executive Control in Breast Cancer
Despite significant progress in understanding cancer and cancer-treatment associated cognitive dysfunction
(CACD), concerns have been raised about the adequacy of traditional neuropsychological tests to accurately
detect cognitive changes reported by patients. Memory deficits are the most commonly reported cognitive
problems among survivors; however, assessment with traditional neuropsychological measures of memory has
frequently demonstrated performance in the normal range. We propose that changes in attentional processes
interfere with efficient and effective encoding of information in memory. Therefore, survivors’ perception of
memory problems is accurate, but related to deficits in attention rather than memory. Traditional
neuropsychological measures: 1) Can have low test-retest reliability over clinically relevant timeframes leading
to large measurement error; 2) Focus on coarsely defined domains of cognitive function while ignoring the
subcomponents of attention critical for later recall; 3) Are unable to measure pre-attentive processes like
sensory gating / filtering; and 4) Do not correlate with self-report of cognitive problems. To address these
limitations, we have developed a battery of well-studied and validated cognitive experimental measures, the
Sensory-Attention-Executive (SAE) battery, which will allow for decomposition of sensory, attentional and
executive sub-processes that underlie efficient learning and encoding of information. We will examine
cognitive changes associated with adjuvant treatment for postmenopausal breast cancer patients treated with
chemotherapy (CT+: N=100) and not treated with chemotherapy (CT-: N=100), who will be assessed prior to
adjuvant treatment, 1 month post-chemotherapy (yoked for CT- patients) and 12 and 24 months post-
enrollment with the SAE battery and traditional neuropsychological measures. Matched healthy controls
(N=100) will be assessed over similar timeframes. The objective of this proposal is to evaluate the following
specific aims: Aim 1: Examine alterations in subcomponents of attention and executive control using the SAE
battery at pretreatment and over time in CT+ and CT- compared to matched, healthy controls; Aim 2: Examine
the prevalence of impairment at pretreatment and over time utilizing the SAE battery versus traditional
neuropsychological measures in CT+ and CT- compared to matched, healthy controls; Aim 3: Examine the
relationship of measures of pre-attentive processing to later, performance-based measures of attention and
memory from the SAE and traditional batteries; and Aim 4: Examine associations between self-report
measures (Sensory Gating Inventory and FACT-Cog) and performance on the SAE battery and traditional
neuropsychological measures. This research is significant because use of the SAE measures could more
precisely identify subcomponents of cognitive processes associated with CACD leading to tailored treatments
and is innovative because it utilizes assessments base on cognitive neuroscience allowing for assessment of
subcomponent cognitive processes along the information processing chain, including pre-attentive processes.
Cognitive Function in Older Adults With Cancer: Assessment, Management, and Research Opportunities.
, Ahles T.
, Chen B.T.
, Mandelblatt J.
, Janelsins M.C.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021-07-01; 39(19), p. 2138-2149.
Prospective evaluation of functional brain activity and oxidative damage in breast cancer: changes in task-induced deactivation during a working memory task.
, Pergolizzi D.
, Pan H.
, Orlow I.
, Passik S.D.
, Silbersweig D.
, Stern E.
, Ahles T.A.
Brain imaging and behavior, 2021 Jun; 15(3), p. 1364-1373.
Strategies to Prevent or Remediate Cancer and Treatment-Related Aging.
, Agurs-Collins T.
, Ahles T.A.
, Campisi J.
, Dale W.
, Demark-Wahnefried W.
, Dietrich J.
, Fuldner R.
, Gallicchio L.
, Green P.A.
, et al.
Journal of the National Cancer Institute, 2021-02-01; 113(2), p. 112-122.